Wheezing and Asthma

Original chapter author: Rasai L. Ernst

Originally published in 2014. Substantially updated and clinically reviewed in 2026 to reflect current evidence, guidelines, and urgent care practice.

Introduction

Asthma is a heterogeneous chronic airway disease characterized by variable respiratory symptoms and variable expiratory airflow limitation. Acute asthma exacerbations are common in urgent care, but wheezing is not synonymous with asthma. First-time wheezing, focal or asymmetric findings, poor response to bronchodilator therapy, or atypical associated symptoms should prompt consideration of an alternative diagnosis.

The urgent care priorities are to identify respiratory compromise early, begin bronchodilator therapy without delay, determine whether the patient can be safely treated in the clinic, and recognize patients who require emergency department (ED) transfer or emergency medical services (EMS). Current asthma strategy also emphasizes that ongoing asthma treatment should contain an inhaled corticosteroid (ICS); short-acting beta₂-agonist (SABA)-only management is no longer preferred for patients with established asthma aged 6 years and older.^1,2

Presentation

• Shortness of breath
• Wheezing
• Chest tightness
• Cough
• Reduced exercise tolerance or difficulty speaking
• In young children: reduced activity, difficulty feeding, retractions, or sleep disturbance from cough/wheeze

Important: Severe airflow obstruction may produce little or no wheeze because air movement is markedly reduced. A quiet or “silent” chest in a distressed patient is an ominous finding.

Triage Pearls

• When respiratory distress is present, treatment and assessment should occur simultaneously. Do not delay bronchodilator therapy while completing a detailed history.
• Immediately assess mental status, ability to speak or drink, respiratory rate, oxygen saturation, work of breathing, accessory muscle use, and air entry.
• Arrange immediate ED transfer/EMS for severe or life-threatening features such as drowsiness or confusion, cyanosis, a quiet/silent chest, inability to speak or drink, oxygen saturation <92% on room air, marked respiratory distress, or worsening despite initial treatment.¹
• Pulse oximetry may overestimate oxygen saturation in patients with darker skin pigmentation; interpret the reading together with the clinical examination and trend.¹
• If anaphylaxis is present with wheezing or asthma, administer intramuscular epinephrine first and manage the asthma concurrently.¹

Practical Severity Assessment for Adults, Adolescents, and Children Aged 6 Years and Older

Feature	Mild	Moderate	Severe / Life-Threatening
Speech / position	Speaks in sentences; can lie down	Speaks in phrases; often prefers sitting	Unable to speak, drink, or lie down; drowsiness/confusion is life-threatening
Work of breathing	None or mild	Increased respiratory rate and accessory muscle use	Marked distress, accessory muscle use, or fatigue
Air entry / wheeze	Normal or mildly reduced	Wheezing with reduced air entry	Very poor air entry or quiet/silent chest
Room-air oxygen saturation	Usually ≥94%	Usually ≥92%	<92% is a severe feature
PEF or FEV1, if feasible	>70% personal best or predicted	50%-70%	<50%

Use the most severe clinical feature to guide management. Objective lung-function testing should not delay treatment or transfer.¹

History Pearls

• Determine whether asthma has been objectively confirmed or whether this is a first episode of wheezing.
• Ask when the last reliever treatment was taken, which inhaler was used, the dose, and the degree and duration of response.
• Ask about previous intubation or mechanical ventilation, ICU care, hospitalization, ED visits, and prior courses of systemic corticosteroids.
• Review the current controller regimen, adherence, access to medication, and inhaler/spacer technique. Heavy reliance on SABA or absence of ICS-containing treatment identifies higher-risk asthma.¹
• Ask about viral symptoms, allergen exposure, tobacco or vaping exposure, occupational triggers, exercise, and medications that can worsen asthma in susceptible patients (eg, nonselective beta-blockers or aspirin/NSAIDs).
• Consider anaphylaxis when wheeze occurs with urticaria, angioedema, hypotension, gastrointestinal symptoms, or a plausible allergen exposure.
• In children, ask about choking or abrupt onset suggesting foreign-body aspiration, especially with focal or unilateral wheezing.
• In adults with unexplained dyspnea or atypical wheezing, consider pulmonary embolism, acute heart failure, or other cardiopulmonary causes rather than assuming asthma.

High-Risk Asthma History

Risk of fatal or near-fatal asthma is increased by prior intubation/mechanical ventilation, recent hospitalization or repeated emergency visits, current or recent systemic corticosteroid use, failure to use ICS-containing therapy, poor adherence, very high SABA use, food allergy/anaphylaxis, and selected psychosocial or medical comorbidities.¹

Physical Exam Pearls

• Obtain a complete set of vital signs, including oxygen saturation, and repeat key findings after treatment.
• Document speech, mental status, respiratory rate, accessory muscle use, air entry, and wheezing before and after bronchodilator therapy.
• Confirm bilateral breath sounds. Unilateral reduction or absence should raise concern for pneumothorax or foreign-body aspiration.
• Stridor or prominent upper-airway noise suggests an alternative diagnosis such as inducible laryngeal obstruction or upper-airway disease.
• Focal crackles, fever, or asymmetric examination findings increase suspicion for pneumonia; diffuse crackles, edema, or jugular venous distention may suggest heart failure.
• In pediatric patients, a validated clinical severity score such as the Pediatric Respiratory Assessment Measure (PRAM) can improve consistency of serial assessment when it is appropriate for the child’s age and local workflow.¹

Testing Pearls

Test	Urgent Care Role
Pulse oximetry	Recommended for acute assessment and serial reassessment. Interpret in clinical context and be aware of possible overestimation in darker skin pigmentation.
PEF or spirometry	Useful when the patient can perform the maneuver safely. Objective airflow measurement helps grade severity and response. Do not delay treatment in a distressed patient.
Chest radiography	Not routine for a typical asthma exacerbation. Consider when pneumonia, pneumothorax, foreign body, heart failure, focal findings, significant fever, chest pain, or an atypical course is suspected.1,2
Blood gas testing	Not routine in urgent care. A patient with suspected ventilatory failure, progressive fatigue, altered mental status, or failure of initial therapy generally requires ED/hospital-level evaluation.
FeNO	May support a diagnosis of Type 2 asthma when the patient is stable and spirometry/PEF is unavailable or nondiagnostic, but it is not required for acute management and a low result does not exclude asthma.1,3

Diagnosis Pearls

For adults, adolescents, and children aged 6 years and older, asthma is diagnosed from a characteristic history of variable respiratory symptoms plus evidence of variable expiratory airflow limitation. When the patient is stable, spirometry with bronchodilator responsiveness is preferred. If spirometry is unavailable, serial PEF measurements can provide supporting objective evidence.¹

Differential Diagnosis of Wheezing in Urgent Care

Condition	Clues
Anaphylaxis	Acute wheeze with urticaria, angioedema, hypotension, gastrointestinal symptoms, or allergen exposure; treat with IM epinephrine first.
Pneumothorax	Sudden dyspnea or pleuritic pain, unilateral decreased breath sounds, poor response to bronchodilator.
Pneumonia	Fever, focal crackles, focal decreased breath sounds, systemic illness.
Inducible laryngeal obstruction	Inspiratory noise/stridor, throat tightness, symptoms disproportionate to lower-airway findings, limited response to bronchodilator.
Pulmonary embolism	Unexplained acute dyspnea, pleuritic pain, hypoxemia, thromboembolic risk factors; wheezing does not exclude PE.
Acute heart failure	Orthopnea, edema, diffuse crackles, elevated JVP, cardiac history.
Foreign-body aspiration	Abrupt onset, choking episode, focal/unilateral wheeze or reduced air entry, especially in children.
Bronchiolitis / viral wheeze	Especially relevant in infants and preschool children; a first wheezing episode in a child younger than 12 months is usually bronchiolitis rather than asthma.1

Wheezing in Children Aged 5 Years and Younger

Asthma can be diagnosed in preschool children, but the diagnosis is primarily clinical. Current GINA guidance emphasizes recurrent wheezing or asthma-like interval symptoms, absence of a more likely alternative cause, and a documented clinical response to asthma therapy. A child whose criteria are not yet complete can be considered to have suspected asthma and reassessed over time.¹

For children aged 0-4 years with recurrent infection-triggered wheezing and no symptoms between infections, the U.S. NAEPP focused update supports a short 7-10 day course of daily ICS started at the onset of a respiratory tract infection together with as-needed SABA, when this strategy is appropriate for the child’s longitudinal asthma plan.³

Treatment and Disposition Pearls

Initial Management

• Use standard resuscitation principles for respiratory arrest or impending arrest.
• Give controlled supplemental oxygen when needed. For adults, adolescents, and children aged 6 years and older, GINA 2026 recommends titrating oxygen to approximately 92%-95%; avoid unnecessary hyperoxia. For children aged 5 years and younger, maintain oxygen saturation at least 92%.¹
• Give inhaled bronchodilator promptly. A pressurized metered-dose inhaler (pMDI) with spacer is effective and is preferred for most mild and moderate presentations when the patient can use it appropriately; nebulization remains appropriate when clinically necessary.¹
• Add inhaled ipratropium to SABA for moderate or severe exacerbations.¹
• Give systemic corticosteroids promptly for moderate or severe exacerbations and for patients whose response to initial bronchodilator therapy is inadequate.¹
• Do not routinely prescribe antibiotics unless there is evidence of a bacterial infection such as pneumonia.^1,2
• Do not use sedatives in an acute asthma exacerbation.^1,2

Common Initial Bronchodilator Doses: Adults, Adolescents, and Children Aged 6 Years and Older

Severity	Initial Inhaled Therapy	Additional Actions
Mild	Albuterol 4 puffs by pMDI + spacer; reassess and repeat once after 30-60 minutes if needed.	Reassess symptoms, oxygen saturation, examination, and lung function when feasible.
Moderate	Albuterol 4-6 puffs + ipratropium 4 puffs by pMDI + spacer; if needed, repeat up to 3 treatments 20-30 minutes apart. Nebulized alternative: albuterol 2.5 mg + ipratropium 0.25 mg.	Start systemic corticosteroid. Escalate/transfer if response is incomplete or the patient worsens.
Severe	Albuterol 6-10 puffs + ipratropium 4 puffs by pMDI + spacer, or nebulized albuterol 5 mg + ipratropium 0.25 mg; repeat as clinically required while arranging transfer.	Controlled oxygen, systemic corticosteroid, continuous monitoring, ED transfer/EMS. IV magnesium sulfate may be considered in severe exacerbations that fail to respond to initial therapy, generally at ED/hospital level.

Inhaler strengths and local protocols vary. The doses above summarize the 2026 GINA acute-care framework rather than reproduce any proprietary algorithm.¹

Systemic Corticosteroids

Population	Common Oral Regimen
Adults	Prednisone/prednisolone up to 50 mg daily for 5-7 days
Children 6-11 years	Prednisone/prednisolone 1-2 mg/kg/day (maximum 40 mg/day) for 3-5 days
Children <2 years	Prednisone/prednisolone 1-2 mg/kg/day (maximum 20 mg/day) for 3-5 days
Children 2-5 years	Prednisone/prednisolone 1-2 mg/kg/day (maximum 30 mg/day) for 3-5 days

Oral corticosteroids are as effective as intravenous corticosteroids for most patients who can swallow and retain medication, and the oral route is preferred. Courses shorter than 2 weeks generally do not require tapering. In young children, dexamethasone 0.3-0.6 mg/kg (maximum 12 mg) as one dose, with or without a second dose the next day, is an evidence-supported alternative to a multi-day prednisolone course.¹

Young Children: Acute Treatment

• For children aged 5 years and younger, albuterol 4 or more puffs (100 mcg/puff) by pMDI + spacer, one puff at a time, is preferred when available; nebulized albuterol 2.5 mg is an alternative.¹
• For moderate or severe presentations, treatment may be repeated about every 20 minutes for up to 3 treatments while response is assessed; add ipratropium when available.¹
• Give systemic corticosteroid for moderate/severe presentations or when hospital-level care is required.
• Arrange immediate hospital transfer for severe or life-threatening features, including drowsiness/confusion, cyanosis, oxygen saturation <92% on room air, marked respiratory distress, or a severe validated clinical score.¹

Controller and Reliever Therapy After an Exacerbation

Current asthma strategy has changed substantially since the original 2014 chapter. For established asthma in adults, adolescents, and children aged 6 years and older, SABA-only treatment should not be the ongoing plan. Patients should receive or continue ICS-containing therapy after an exacerbation, with the exact regimen based on age, prior treatment, asthma severity, formulary, and continuity plan.^1,2

GINA favors ICS-formoterol-based anti-inflammatory reliever strategies for many patients, while the U.S. NAEPP 2020 focused update recommends single maintenance-and-reliever therapy (SMART) with ICS-formoterol for selected patients aged 4 years and older with moderate-to-severe persistent asthma.³ U.S. regulatory labeling is not identical to GINA strategy: currently marketed budesonide-formoterol products are not FDA-indicated for relief of acute bronchospasm, whereas albuterol-budesonide (Airsupra) is FDA-approved as an as-needed reliever for adults aged 18 years and older and also reduces exacerbation risk.^4,5 Urgent care clinicians should align any new controller/reliever prescription with U.S. labeling, local formulary, and the patient’s established asthma plan.

Levalbuterol

Levalbuterol remains an available SABA, but evidence has not demonstrated a consistent clinically meaningful advantage over racemic albuterol for acute asthma. It should not routinely be substituted solely to avoid tachycardia.⁶

Disposition

Disposition	Practical Criteria
Treat and discharge from urgent care	Clear sustained improvement after treatment; no severe features; symptoms and examination have returned to a mild range for at least 1-2 hours after the last albuterol treatment when observation is feasible; room-air oxygen saturation ≥92%; PEF/FEV1 >70% personal best or predicted when measured; adequate access to medications and follow-up.1
ED transfer / hospital evaluation	Oxygen saturation <92% on room air; persistent moderate/severe work of breathing; need for SABA more often than every 1-2 hours; incomplete response or worsening after initial treatment; persistent dyspnea several hours after systemic corticosteroid; significant diagnostic uncertainty; high-risk asthma history; or limited ability to manage safely outside a hospital.1
Call EMS / emergent transfer	Drowsiness, confusion, cyanosis, quiet/silent chest, impending respiratory failure, inability to speak/drink, severe hypoxemia, hemodynamic instability, anaphylaxis with instability, or rapid clinical deterioration.
Specialty / primary care follow-up	Uncertain diagnosis, recurrent exacerbations, repeated systemic corticosteroid courses, poor asthma control despite appropriate ICS-containing therapy, suspected occupational asthma, or other features suggesting difficult-to-treat/severe asthma.

Care Algorithm

1. Assess immediately: confirm that symptoms are likely lower-airway asthma while checking for anaphylaxis, pneumothorax, pneumonia, upper-airway obstruction, pulmonary embolism, heart failure, or foreign body when clinically appropriate.
2. Grade severity: speech, mental status, respiratory rate, accessory muscle use, air entry, oxygen saturation, and PEF/FEV₁ when feasible.
3. Treat promptly: inhaled bronchodilator; oxygen if needed; add ipratropium and systemic corticosteroid for moderate/severe disease.
4. Reassess early: repeat vital signs, oxygen saturation, work of breathing, air entry, and objective lung function when feasible.
5. Escalate: if severe at presentation, worsening, or incompletely responsive, arrange ED transfer/EMS while continuing bronchodilator, oxygen, and corticosteroid treatment.
6. Before outpatient disposition: confirm sustained clinical improvement and ensure that ongoing asthma treatment includes an appropriate ICS-containing strategy rather than SABA-only therapy for established asthma in patients aged 6 years and older.

Medicolegal Pearls

• Document the patient’s initial severity, oxygen saturation, work of breathing, air entry, treatments given, and objective response to therapy.
• Document high-risk history such as prior intubation/ICU care, recent hospitalization, repeated emergency visits, systemic corticosteroid use, and high SABA use.
• A lack of wheezing does not exclude severe asthma. A distressed patient with poor air entry or a silent chest requires emergent escalation.
• Do not anchor on asthma when the presentation is atypical. Reconsider pneumothorax, anaphylaxis, pulmonary embolism, pneumonia, heart failure, inducible laryngeal obstruction, and foreign-body aspiration when the clinical pattern or response to treatment does not fit.
• Failure to improve after appropriate initial urgent care therapy is itself a reason to reassess the diagnosis and level of care.

References

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2026. https://ginasthma.org/2026-gina-strategy-report/
2. Global Initiative for Asthma. Summary Guide for Asthma Management and Prevention. 2026. https://ginasthma.org/2026-gina-summary-guide/
3. Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217-1270. doi:10.1016/j.jaci.2020.10.003.
4. US Food and Drug Administration. FDA approves drug combination treatment for adults with asthma. January 11, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma
5. US Food and Drug Administration. Symbicort Aerosphere prescribing information. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216579s001lbl.pdf
6. Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis. Pulm Pharmacol Ther. 2013;26(2):239-248. doi:10.1016/j.pupt.2012.11.003.